Understanding Checkpoint Inhibitors in NSCLC

Program Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Credit Expired

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Faculty

Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

Featured RMEI CE Activities – Earn CE Credit(s)

Case Challenges in Hereditary Angioedema: Innovative Therapeutic Strategies for a Normal Life: A Care Team Forum®

1.5 CE Credit(s)

A Balancing Act: Safety and Success in CMV Management for HCT Patients: A Clinical Forum®

1.0 CE Credit(s)

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®